Neobe Therapeutics, a pioneering synthetic biology startup at the forefront of immuno-oncology innovation, is thrilled to announce the successful closure of a $2.34m financing round. This significant financial milestone was achieved with the support of new investors Pioneer Group and 2048 Ventures, alongside existing backers Deep Science Ventures*, Cancer Research Horizons*, and Discovery Park Ventures. Additionally, the round received a non-dilutive grant award from UKRI’s Innovate UK Future Economy Investor Partnership Programme.
News
Neobe Therapeutics raises over $2m for synthetic biology enabled tumour microenvironment remodelling
Discovery Park to host two events to celebrate women in business and tackle challenges in women’s health.
Discovery Park, Kent’s thriving life science community, is marking International Women’s Day by supporting women in business and tackling gender bias in healthcare.
In a recent blog post – AMSBIO describe how life science research groups are using their BioPORTER®, Detachin™, and SoluLyse™ reagents to make groundbreaking advances in Parkinson’s research, hypersomnia studies and eco-friendly microbial ester production.
These novel reagents empower research by enhancing the efficiency, accuracy, and reproducibility of scientific investigations.
Cambridge, UK 23 February 2024
We are pleased to announced the shortlist for the One Nucleus Awards 2024.
The One Nucleus Award categories are structured to reflect that breadth of R&D, investment, service provision and enabling support across the stakeholders. “Performance of the Year” being recognised in each category. The awards criteria recognise success between 1 December 2022 – 30 November 2023.
Best Performing Facilities Provider of the Year:
Cambridge, UK 23 February 2024 - We are thrilled to announce the winners of the One Nucleus Boston Bootcamp competition aimed at providing a focused ‘Getting US-ready’ experience.
Congratulations to:
Aleta Biotherapeutics (Aleta), a clinical stage, immuno-oncology company with a CAR T-cell engager (CTE) platform that enables cell cancer therapies to work more effectively, and Cancer Research UK’s Centre for Drug Development, today announce the first patient was dosed in a Phase 1/2 clinical trial. This trial is evaluating the Company’s first-in-class biologic CAR T-cell engager, ALETA-001, for the treatment of patients with B-cell malignancies who are relapsed/refractory to CD19-targeting CAR T-cell therapy.
Biocair, an award-winning life science logistics expert, is pleased to announce the opening of its office in Bangalore, the company’s fourth office in India. Spread over 2500 square feet, the new office was inaugurated by Neha Naik, General Manager Biocair India, on February 13 alongside key customers and key partners. Biocair first established operations in the country in 2021 with its corporate office in Mumbai and other locations in New Delhi and Chennai.
• Rapid development and clinical validation of diagnostics that enable innovative clinical care pathways in complex, chronic diseases
• Targeted precision medicine clinical trials leveraging a complementary diagnostic approach are expected to readout results as early as this year
We recently conducted a survey to help us and the businesses we represent better understand the future of recruitment.
In light of the enduring challenges posed by the cost of living crisis for both job seekers and organisations, our goal was to collect valuable data. We hope this information empowers businesses to make informed decisions and shape effective recruitment strategies, aiding their success in a volatile market, not only for 2024 but for the years ahead.
Summary of findings:
Following the success of three previous events of a similar format, the Anglia Innovation Partnership (AIP) team, the science park management company, at Norwich Research Park will continue to hold enterprise showcase events throughout 2024 to demonstrate the strength of enterprise, innovation, research and collaboration across the campus that has been delivered through the ongoing campus-wide enterprise strategy.